Hartmann Radiotherapy and Radiosurgery Institute, 4 rue Kleber, 92200, Levallois Perret, Ile de France, France.
Integrative medecine department, Rafael Institute, Levallois Perret, France.
Strahlenther Onkol. 2023 Apr;199(4):420-424. doi: 10.1007/s00066-023-02054-0. Epub 2023 Mar 2.
Treatment options for renal cell carcinoma (RCC) with inferior vena cava tumor thrombus (IVC-TT) are limited and carry substantial risks. Currently, there are no standard treatment options in the setting of recurrent or unresectable RCC with IVC-TT.
We report our experience of treating an IVC-TT RCC patient with stereotactic body radiation therapy (SBRT).
This 62-year-old gentleman presented renal cell carcinoma with IVC-TT and liver metastases. Initial treatment consisted of radical nephrectomy and thrombectomy followed by continuous sunitinib. At 3 months, he developed an unresectable IVC-TT recurrence. A fiducial marker was implanted into the IVC-TT by catheterization. New biopsies were performed at the same time, demonstrating a recurrence of the RCC. SBRT consisted of 5 fractions of 7 Gy to the IVC-TT with excellent initial tolerance. He subsequently received anti-PD1 therapy (nivolumab). At 4 years follow-up, he is doing well with no IVC-TT recurrence and no late toxicity.
SBRT appears to be a feasible and safe treatment for IVC-TT secondary to RCC in patients who are not candidates for surgery.
肾细胞癌(RCC)合并下腔静脉肿瘤血栓(IVC-TT)的治疗选择有限,且风险较大。目前,对于复发性或不可切除的 RCC 合并 IVC-TT,尚无标准的治疗选择。
我们报告了使用立体定向体部放射治疗(SBRT)治疗 IVC-TT RCC 患者的经验。
这位 62 岁的男性患有 RCC 合并 IVC-TT 和肝转移。初始治疗包括根治性肾切除术和血栓切除术,随后进行舒尼替尼连续治疗。3 个月时,他出现了不可切除的 IVC-TT 复发。通过导管将基准标记物植入 IVC-TT。同时进行了新的活检,结果显示 RCC 复发。SBRT 包括对 IVC-TT 进行 5 次 7Gy 的分割照射,初始耐受性良好。随后他接受了抗 PD1 治疗(nivolumab)。4 年随访时,他情况良好,IVC-TT 无复发,无晚期毒性。
对于不适合手术的 RCC 继发 IVC-TT 患者,SBRT 似乎是一种可行且安全的治疗方法。